Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2496-2504

  Casado, Enrique ^a,c,d   Gomez Navarro, Jesus ^a,c   Yamamoto, Masato ^a,c   Adachi, Yasuo ^a,c   Coolidge, Candace J ^a,c   Arafat, Waleed O ^a,c   Barker, Shannon D ^a,c   Wang, Minghui H ^a,c   Mahasreshti, Parameshwar J ^a,c   Hemminki, Akseli ^a,c   Gonzalez Baron, Manuel ^d   Barnes, Mack N ^b   Pustilnik, Terri B ^b   Siegal, Gene P ^b,c   Alvarez, Ronald D ^b   Curiel, David T ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLOOXYGENASE 2; LUCIFERASE; MIDKINE; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SCID MOUSE; TRANSCRIPTION REGULATION; TRANSGENE;

ANIMALS; CARRIER PROTEINS; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2; CYTOKINES; EPITHELIAL CELLS; FEMALE; GANCICLOVIR; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEPATITIS; HERPESVIRUS 1, HUMAN; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, SCID; OVARIAN NEOPLASMS; PERITONITIS; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THYMIDINE KINASE; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0034881238     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Strategies to adapt adenoviral vectors for targeted delivery
2. Replicative adenoviruses for cancer therapy
3. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA
4. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene
5. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter
6. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors
7. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
8. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma
9. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene
10. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach
11. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
12. Replication-selective adenoviruses as oncolytic agents
13. Gene therapy: Designer promoters for tumor targeting
14. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants
15. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors
16. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses
17. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration
18. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration
19. Gene therapy for cancer
20. In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines
21. Strategy for achieving selective killing of carcinomas
22. A recombinant adenoviral vector with selective transgene expression in ovarian cancer cells
23. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
24. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells
25. L-plastin promoter confers tumor-specific gene expression and tumor-specific conditional replication competency of adenoviral vectors
26. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers
27. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites
28. Anti-TAG-72 antibody B72.3-immunological and clinical effects in ovarian carcinoma
29. Isolation, culture and characterization of human peritoneal mesothelial cells
30. A simplified system for generating recombinant adenoviruses
31. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells
32. Structure and expression of the human prostaglandin endoperoxide synthase 2 gene
33. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)
34. Genetic targeting of adenoviral vectors
35. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo
36. Comparison of long-term survival of cytomegalovirus promoter versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer